Buffington Mohr McNeal’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $10.8M | Sell |
21,714
-5,017
| -19% | -$2.72M | 2.13% | 19 |
|
|
2024
Q4 | $13.9M | Sell |
26,731
-491
| -2% | -$270K | 2.31% | 15 |
|
|
2024
Q3 | $16.8M | Sell |
27,222
-195
| -0.7% | -$115K | 2.77% | 9 |
|
|
2024
Q2 | $15.2M | Sell |
27,417
-272
| -1% | -$156K | 2.66% | 10 |
|
|
2024
Q1 | $16.1M | Sell |
27,689
-32
| -0.1% | -$18K | 2.91% | 7 |
|
|
2023
Q4 | $14.7M | Sell |
27,721
-247
| -0.9% | -$120K | 2.96% | 7 |
|
|
2023
Q3 | $14.2M | Buy |
27,968
+26
| +0.1% | +$13.9K | 3.22% | 6 |
|
|
2023
Q2 | $14.6M | Sell |
27,942
-320
| -1% | -$173K | 3.15% | 7 |
|
|
2023
Q1 | $16.3M | Sell |
28,262
-391
| -1% | -$220K | 3.73% | 7 |
|
|
2022
Q4 | $15.8M | Sell |
28,653
-711
| -2% | -$377K | 3.67% | 6 |
|
|
2022
Q3 | $14.9M | Buy |
29,364
+24
| +0.1% | +$13.4K | 3.59% | 6 |
|
|
2022
Q2 | $15.9M | Sell |
29,340
-760
| -3% | -$418K | 3.49% | 6 |
|
|
2022
Q1 | $17.8M | Sell |
30,100
-1,623
| -5% | -$932K | 3.37% | 7 |
|
|
2021
Q4 | $21.2M | Buy |
31,723
+75
| +0.2% | +$46.8K | 3.62% | 7 |
|
|
2021
Q3 | $18.1M | Sell |
31,648
-331
| -1% | -$182K | 3.47% | 7 |
|
|
2021
Q2 | $16.1M | Sell |
31,979
-1
| -0% | -$472 | 3.16% | 7 |
|
|
2021
Q1 | $14.6M | Sell |
31,980
-138
| -0.4% | -$65.9K | 3.13% | 7 |
|
|
2020
Q4 | $15M | Buy |
32,118
+605
| +2% | +$284K | 3.48% | 8 |
|
|
2020
Q3 | $13.9M | Sell |
31,513
-232
| -0.7% | -$95.8K | 3.67% | 8 |
|
|
2020
Q2 | $11.5M | Sell |
31,745
-341
| -1% | -$114K | 3.24% | 8 |
|
|
2020
Q1 | $9.1M | Buy |
32,086
+675
| +2% | +$213K | 3.03% | 9 |
|
|
2019
Q4 | $10.2M | Buy |
31,411
+62
| +0.2% | +$18.8K | 2.89% | 9 |
|
|
2019
Q3 | $9.13M | Buy |
31,349
+325
| +1% | +$93.1K | 2.8% | 10 |
|
|
2019
Q2 | $9.11M | Sell |
31,024
-110
| -0.4% | -$30.3K | 2.85% | 10 |
|
|
2019
Q1 | $8.52M | Buy |
31,134
+644
| +2% | +$160K | 2.74% | 10 |
|
|
2018
Q4 | $6.82M | Buy |
30,490
+228
| +0.8% | +$53.5K | 2.74% | 8 |
|
|
2018
Q3 | $7.39M | Buy |
30,262
+378
| +1% | +$87K | 2.55% | 9 |
|
|
2018
Q2 | $6.19M | Sell |
29,884
-321
| -1% | -$68.1K | 2.32% | 10 |
|
|
2018
Q1 | $6.24M | Buy |
30,205
+795
| +3% | +$167K | 2.39% | 10 |
|
|
2017
Q4 | $5.58M | Sell |
29,410
-75
| -0.3% | -$14.4K | 2.14% | 12 |
|
|
2017
Q3 | $5.67M | Buy |
29,485
+541
| +2% | +$98K | 2.21% | 10 |
|
|
2017
Q2 | $5.05M | Buy |
28,944
+18,053
| +166% | +$3.03M | 1.99% | 10 |
|
|
2017
Q1 | $1.67M | Buy |
10,891
+2,026
| +23% | +$310K | 0.74% | 42 |
|
|
2016
Q4 | $1.25M | Buy |
8,865
+117
| +1% | +$17.3K | 0.48% | 49 |
|
|
2016
Q3 | $1.39M | Sell |
8,748
-167
| -2% | -$25.7K | 0.58% | 44 |
|
|
2016
Q2 | $1.32M | Sell |
8,915
-660
| -7% | -$97.4K | 0.58% | 44 |
|
|
2016
Q1 | $1.36M | Buy |
9,575
+4,025
| +73% | +$539K | 0.6% | 40 |
|
|
2015
Q4 | $787K | Buy |
+5,550
| New | +$740K | 0.42% | 45 |
|
Other funds holding TMO
Buffington Mohr McNeal's TMO Position: Q1 2025 in Review
Buffington Mohr McNeal reduced its Thermo Fisher Scientific (TMO) stake by 19% in Q1 2025, selling an estimated $2.72M and leaving 21,714 shares worth $10.8M. The position accounts for 2.13% of the portfolio, ranked #19.
Buffington Mohr McNeal first reported a position in TMO in Q4 2015 and has held it in 38 quarters since. The position peaked at $21.2M in Q4 2021. 2,571 funds tracked by Wall St. Rank hold TMO as of Q1 2025.
- Buffington Mohr McNeal held 21,714 shares of Thermo Fisher Scientific worth $10.8M as of Q1 2025.
- Buffington Mohr McNeal sold 5,017 Thermo Fisher Scientific shares in Q1 2025, an estimated $2.72M.
- Thermo Fisher Scientific made up 2.13% of Buffington Mohr McNeal's portfolio in Q1 2025, its #19 holding.
- Buffington Mohr McNeal first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 38 quarters since.
- Buffington Mohr McNeal's Thermo Fisher Scientific position peaked at $21.2M in Q4 2021.
- 2,571 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2025.
Based on Buffington Mohr McNeal's 13F filing for Q1 2025, filed 28 Apr 2025.